Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

hat_are_the_key_statistics_for_stomach_cancer_40.asp?rnav=cri" target="_new">http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_stomach_cancer_40.asp?rnav=cri. Accessed on December 23, 2008.

(3) Ohtsu, A. Chemotherapy for metastatic gastric cancer: past, present, and future. J Gastroenterol 2008; 43:256-264.

(4) American Cancer Society. Overview: Stomach Cancer. Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_2_2X_What_causes_stomach_cancer_40.asp?sitearea=. Accessed on December 23, 2008.

Novartis Media Relations

    Media only:                               Investors only:
    Denise Brashear                           Jill Pozarek
    Novartis Oncology                         Novartis Corporation
    P: +1 862 778 7336                        P: +1 212 830 2445
    F: +1 917 453 2665

    Dana Kahn Cooper
    P: +1 732 817 1800
    F: +1 732 817 1834


'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 PharmaEngine, Inc. (TWO:4162) today announced ... MACK ) with its sublicensing partner, Baxter ... that Baxter has submitted a marketing authorization application ... MM-398 (irinotecan liposome injection), also known as "nal-IRI," ... who have been previously treated with gemcitabine-based therapy. ...
(Date:5/4/2015)... , May 4, 2015 Bayer HealthCare (Bayer) ... Pharmaceuticals, Inc. (NASDAQ: ISIS ) on ISIS-FXI Rx, ... the prevention of thrombosis. Under the agreement Bayer will ... of high unmet medical need. As part of the ... profile of ISIS-FXI Rx in an appropriate patient ...
(Date:5/4/2015)... 4, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXI Rx ... of the agreement, Isis is eligible to receive up ... $100 million up-front payment and a $55 million payment ... study in patients with compromised kidney function. Isis is ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 2Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 3Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 4Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis 5
... April 26, 2011 Cadence Pharmaceuticals, Inc. ... on in-licensing, developing and commercializing proprietary products principally for ... company,s President and CEO Theodore Schroeder will present a ... month of May: Deutsche Bank,s 36th ...
... Lilly and Company (NYSE: LLY ) and Medtronic, ... entered into a collaboration to research and develop a new ... new  medicine to the brain using an implantable drug delivery ... therapeutic approach for Parkinson,s disease that combines the strengths of ...
Cached Medicine Technology:Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease 2Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease 3
(Date:5/4/2015)... Every Friday afternoon at A Forever Recovery, a result-driven ... and staff gather in the common room to celebrate ... to gain encouragement and inspiration in their continuing effort ... those patients who have completed their recovery programs come ... share a bit about their journey with the audience. ...
(Date:5/4/2015)... Global Vision, the industry leader ... announced that it will showcase Proofware at the ... in Nashville Tennessee, May 04 and May 05. ... all-in-one we-based packaging inspection suite, giving enterprise-wide instant ... their brand copy and artwork. Proofware offers a ...
(Date:5/4/2015)... MO (PRWEB) May 04, 2015 Leonardo ... president and chief physician executive, and William C. Daniel, ... received and accepted personal invitations from the Secretary of ... Security Forum (NSF) at the Air War College, Maxwell ... to expose influential citizens to senior U.S. and international ...
(Date:5/4/2015)... 2015 Milton Hershey School® has named ... of the Year, recognizing his commitment to pediatric cancer ... sets for MHS students. , “Dr. Graves is a ... children are provided a top-notch education, a nurturing environment, ... said Pete Gurt ’85, president of MHS. “He is ...
(Date:5/4/2015)... McNeil & Company , a nationwide ... coverage for its Emergency Services Insurance Program ... and proactive risk management to the emergency services industry. ... providing our customers with unparalleled service and the best ... are excited to launch over 100 new enhancements that ...
Breaking Medicine News(10 mins):Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3
... edition Mustang at the New York, International Auto Show to raise money for ... ... G. Komen Race for the Cure - to $500 ... dedicated more than $95 million in, cash and in-kind contributions for breast cancer education ...
... Placing a "super-long coffee order,",a quirky trait ... a,difference for Children,s Hospital and Regional Medical Center., ... $1 to Children,s,Hospital for every Tully,s Coffee customer ... unique concoctions made up of seemingly,incongruous ingredients and ...
... BETHESDA, Md., March 18 /Xinhua-PRNewswire/ -- Chindex International,Inc. (Nasdaq: ... Board of,Directors has unanimously approved a three-for-two split of ... per share, including its Class,B Common Stock. Stockholders of ... 2008 will receive one-half additional share of Common Stock ...
... March 18 W. Scott Harkonen,M.D., the former ... fraud and,felony Food, Drug and Cosmetic Act charges ... false and misleading information about the efficacy of,InterMune,s ... pulmonary fibrosis (IPF), the Justice Department announced,today., ...
... Statement Is Contrary to Widely Held American Values, ... and CEO, Religious,Coalition for Reproductive Choice, WASHINGTON, ... the national coalition of mainstream religious and,religiously affiliated ... reproductive healthcare and for women themselves in,the statement ...
... 18 Leading experts and,distinguished faculty in ... protocols and research to over 400 multi-disciplinary,clinicians ... Disorders,Professionals Symposium (iaedp(TM)) ( http://www.iaedp.com/ ) April ... in Orlando, Florida., "This year,s symposium ...
Cached Medicine News:Health News:Ford Launches 'Warriors in Pink' Mustang for '09, Doubles Contributions To Race For The Cure 2Health News:PEMCO Insurance and Tully's Coffee Team Up to Make Coffee Orders Count - For Children's Hospital 2Health News:PEMCO Insurance and Tully's Coffee Team Up to Make Coffee Orders Count - For Children's Hospital 3Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 2Health News:Chindex International, Inc. Announces Three-For-Two Stock Split 3Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 2Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 3Health News:Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations 4Health News:National Religious Coalition Deeply Concerned by HHS Secretary's Disregard for Women's Reproductive Health 2Health News:Eating Disorders Take Center Stage at iaedp(TM) 2008 Symposium in Orlando, Florida 2
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... The total ergonomic solution and best ... Soft, feather touch action and ultra lightweight ... Stress-free tip ejection with long, lever tip ... identification , Accepts universal tips or for ...
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
Medicine Products: